| Identification | Back Directory | [Name]
OLPRINONE HYDROCHLORIDE | [CAS]
119615-63-3 | [Synonyms]
e1020
Coretec
OLPRINONE HCL
xo-,monohydrochloride,monohydrate
3-pyridinecarbonitrile,1,2-dihydro-5-(imidazo(1,2-a)pyridin-6-yl)-6-methyl-2-o
1,2-Dihydro-5-imidazo[1,2-α]pyridin-6-yl-6-methyl-2-oxo-3-pyridinecarbonitrile Hydrochloride
3-Pyridinecarbonitrile,1,2-dihydro-5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-,monohydrochloride
Loprinone hydrochloride, 1,2-Dihydro-5-(imidazo[1,2-a]pyridin-6-yl)-6-methyl-2-oxo-3-pyridinecarbonitrile hydrochloride | [Molecular Formula]
C14H10N4O.ClH.H2O | [MDL Number]
MFCD01749474 | [MOL File]
119615-63-3.mol | [Molecular Weight]
304.736 |
| Chemical Properties | Back Directory | [Appearance]
Off-White Crystalline Powder | [Melting point ]
>3000C | [storage temp. ]
2-8°C
| [solubility ]
DMSO: ≤4 mg/mL
| [form ]
solid
| [color ]
beige
|
| Hazard Information | Back Directory | [Chemical Properties]
Off-White Crystalline Powder | [Uses]
Inotropic agent which inhibits cAMP phosphodiesterase. Cardiotonic | [Description]
Coatec was launched in Japan for acute cardiac insufficiency in cases
resistant to other treatments. There are three related synthetic routes, 5-6 steps
each, to loprinone all converging on 1-(imidazo[1,2a]pyridyl-6-yl)-Zpropanone as an
advanced intermediate. It is a potent and selective inhibitor of PDE Ⅲ and a long
lasting, orally active, positive inotropic agent. The PDE Ⅲ inhibition caused
increased levels of CAMP which leads to the positive inotropic effect that was not
altered by β or H2-preceptor antagonists. It was 100 times less potent at PDE I and
PDE Ⅱ with no Na-K-ATPase activity. Improved hemodynamic parameters with slight
changes in heart rate and blood pressure were seen in vivo. It is not mutagenic and
its primary metabolite was less active. | [Originator]
Eisai (Japan) | [Definition]
ChEBI: Olprinone hydrochloride is an organic molecular entity. | [Brand name]
Coatec |
|
|